A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Saturday, 16 JUNE 2018
In randomized studies (RCTs: MOBILITY, TARGET and MON-ARCH), and open-label [OLE] EXTEND, for those patients who experienced decreases in ANC this typically occurred early after initiating sarilumab. For sarilumab patients with decreased ANC in the RCTs and the OLE, we assessed the outcomes associated with either continuing treatment, decreasing the sarilumab dose or delaying the dose. Objectives: The effects of a dose decrease (200 to 150 mg), dose delay (>17 days), vs no change in treatmentdoi:10.1136/annrheumdis-2018-eular.1371 fatcat:w2kfrn7npncplj46wzmoihygma